Last updated: February 19, 2026
This report provides a detailed analysis of World Intellectual Property Organization (WIPO) patent application WO2019071111, focusing on its claimed subject matter, the scope of its protection, and its position within the broader patent landscape. The application, filed by Merck Sharp & Dohme Corp., pertains to novel compounds and their use in treating viral infections, specifically hepatitis C virus (HCV).
What is the Core Innovation Claimed by WO2019071111?
WO2019071111 claims novel chemical entities belonging to a specific structural class, described as substituted pyrazole derivatives. These compounds are characterized by a particular arrangement of functional groups on a pyrazole core, designed to inhibit viral replication. The application also claims pharmaceutical compositions comprising these compounds and methods of treating viral infections, particularly HCV, using these compositions.
The chemical structures disclosed are exemplified by specific compounds, such as those listed in the patent application. For instance, WO2019071111 describes a general formula (I) where R1, R2, R3, and R4 represent various substituents, including alkyl groups, aryl groups, heteroaryl groups, halogens, and amino functionalities. The exact nature and position of these substituents are critical to the claimed activity and patentability.
The primary utility of these novel compounds lies in their potential as antiviral agents. The patent application details in vitro data demonstrating the inhibitory effect of representative compounds against HCV replication. This inhibition is often achieved by targeting specific viral enzymes or proteins essential for the viral life cycle. While the application does not explicitly name the target, the structural class and efficacy data suggest mechanisms of action common to known antiviral therapies, such as polymerase or protease inhibition.
What is the Geographic and Temporal Scope of Protection?
WO2019071111 is an international patent application filed under the Patent Cooperation Treaty (PCT). This means it has the potential to be nationalized and granted in numerous member countries. As of its publication date of April 11, 2019, it provides a unified filing basis for seeking patent protection in designated states.
The application was filed on October 5, 2018, with an earlier priority date claimed from an international application filed on October 6, 2017. The priority date is crucial as it establishes the “date of invention” for novelty and inventive step assessments. The international publication number is WO2019/071111 A1.
Following the international phase, the applicant typically enters the national or regional phase in countries or regions where protection is desired. This process involves translating the application and paying national fees. Each national patent office then examines the application according to its own laws and regulations.
The ultimate geographic scope of protection depends on which countries Merck Sharp & Dohme Corp. chooses to pursue patent grants. Common jurisdictions for pharmaceutical patents include the United States, European Patent Office (EPO) member states, Japan, China, and other major pharmaceutical markets. The temporal scope of protection for granted patents will typically be 20 years from the earliest priority date, subject to potential extensions for regulatory delays (e.g., Supplementary Protection Certificates in Europe or Patent Term Extensions in the U.S.).
What Specific Claims are Asserted in WO2019071111?
WO2019071111 asserts a series of claims, typically progressing from broad genus claims to narrower, specific compound claims, and then to claims covering formulations and methods of use.
Key Claim Categories Typically Found in Such Applications:
- Compound Claims: These are the core of the patent. They claim the novel chemical entities themselves. Often, these start with a broad generic "Markush" claim encompassing a structural formula with variable substituents (R groups), followed by specific exemplified compounds. For example, Claim 1 might define a general formula (I), and subsequent claims might specify particular values for R1, R2, R3, and R4, or claim specific compounds by their chemical names or structural diagrams.
- Pharmaceutical Composition Claims: These claims cover formulations containing one or more of the claimed compounds as an active pharmaceutical ingredient (API) along with pharmaceutically acceptable carriers, excipients, or diluents. This broadens protection to the drug product itself.
- Method of Treatment Claims: These claims cover the use of the claimed compounds or compositions to treat specific diseases or conditions, most notably HCV infection. These claims are vital for protecting the therapeutic application of the invention.
- Use Claims: Often related to method of treatment claims, these can specify the use of a compound for the manufacture of a medicament for treating a particular condition.
The exact wording and scope of each claim are critical. For instance, the definition of the R groups in the generic compound claims dictates the breadth of the invention. Narrowly defined R groups limit the scope, while broadly defined ones extend it. The claims also define the precise scope of the method of treatment, specifying the type of viral infection, dosage regimens, and patient populations.
The claims in WO2019071111 aim to prevent competitors from making, using, selling, offering for sale, or importing the claimed compounds, compositions, or methods of treatment without authorization.
What is the Patent Landscape for Hepatitis C Virus (HCV) Therapeutics?
The patent landscape for HCV therapeutics is highly competitive and characterized by extensive patenting by multiple pharmaceutical companies. Significant innovation has led to the development of highly effective direct-acting antiviral (DAA) agents that have revolutionized HCV treatment.
Key Players and Their Contributions:
- Gilead Sciences: Known for its blockbuster DAAs such as Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), which target the NS5B polymerase and NS5A protein, respectively. Gilead has a robust patent portfolio covering these molecules, formulations, and treatment regimens.
- AbbVie: Developed direct-acting antiviral regimens like Viekira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir) and Mavyret (glecaprevir/pibrentasvir), targeting protease (NS3/4A) and NS5A. AbbVie also holds extensive patent protection.
- Janssen Pharmaceuticals (Johnson & Johnson): Developed Olysio (simeprevir), a protease inhibitor, and part of combination therapies.
- Bristol-Myers Squibb: Contributed Daklinza (daclatasvir), an NS5A inhibitor.
Patent Trends in HCV:
- Nucleotide/Nucleoside Analogues: A significant portion of early HCV DAA patents focused on nucleotide and nucleoside analogues that inhibit viral RNA-dependent RNA polymerase (RdRp), such as sofosbuvir.
- Non-Nucleoside Inhibitors: Patents for non-nucleoside inhibitors targeting various viral proteins, including NS3/4A protease, NS5A protein, and NS5B polymerase, are prevalent. These often involve complex heterocyclic structures.
- Combination Therapies: Due to the high barrier to resistance and improved efficacy, many patents cover fixed-dose combinations of multiple DAAs targeting different viral proteins.
- Second-Generation Compounds: As the field matures, patent activity shifts towards next-generation compounds with improved potency, broader genotypic coverage, reduced side effects, and simplified dosing regimens. WO2019071111 likely falls into this category, seeking to improve upon existing therapies.
- Formulations and Delivery Systems: Beyond novel active ingredients, patents also protect specific formulations, salt forms, polymorphs, and delivery methods that offer advantages in stability, bioavailability, or patient compliance.
- Therapeutic Regimens: Patents can cover specific dosing schedules, durations of treatment, and combinations of drugs for treating particular patient subgroups or genotypes.
Implications for WO2019071111:
The presence of numerous existing patents in the HCV space means that WO2019071111 will undergo rigorous examination. Competitors' patents covering similar structural classes, target proteins, or therapeutic approaches could limit the effective scope or enforceability of any granted patent from this application. Merck Sharp & Dohme Corp. would have conducted extensive freedom-to-operate (FTO) analyses to assess potential infringements and patentability prior to filing. The novelty and inventiveness of the claimed compounds must be clearly distinguishable from prior art, including existing HCV therapeutics and their associated patent literature.
What Are the Potential R&D and Investment Implications?
The R&D and investment implications of WO2019071111 are tied to its potential to address unmet needs in HCV treatment or offer advantages over existing therapies.
R&D Implications:
- Pipeline Enhancement: For Merck Sharp & Dohme Corp., successful patent protection for these novel compounds would bolster their antiviral pipeline, potentially leading to new therapeutic options for HCV patients.
- Mechanism of Action Exploration: Further R&D would be required to fully elucidate the mechanism of action, determine optimal therapeutic regimens, assess safety and efficacy in clinical trials, and establish pharmacokinetic and pharmacodynamic profiles.
- Combination Strategies: Investigating combinations of these novel compounds with existing DAAs could be a strategic R&D path to achieve higher cure rates, overcome resistance, or reduce treatment duration.
- Intellectual Property Strategy: The application signals a strategic investment in antiviral research, aiming to secure a competitive position in a mature but still evolving market.
Investment Implications:
- Market Opportunity: Despite significant treatment advances, a residual market for HCV therapeutics remains, particularly for specific patient populations or in regions with access challenges. New, highly effective therapies can still capture market share.
- Competitive Threat: If WO2019071111 leads to a successful drug, it represents a potential competitive threat to existing market leaders. Investors would monitor its progress through clinical development and regulatory approval.
- Valuation of Merck's Portfolio: The strength and breadth of Merck's patent portfolio, including applications like WO2019071111, contribute to the overall valuation of the company. Investors assess such patents as indicators of future revenue potential.
- Licensing and Partnership Opportunities: The novelty of the compounds could present opportunities for licensing agreements or co-development partnerships, allowing other companies to leverage Merck's IP.
- Due Diligence: For investors considering stakes in companies with HCV portfolios or considering acquisitions, understanding the patent landscape, including applications like WO2019071111, is critical for due diligence.
The success of any drug developed from WO2019071111 will ultimately depend on its clinical performance, regulatory approval, market access, and the ability of Merck Sharp & Dohme Corp. to defend its intellectual property against competitors.
Key Takeaways
- WIPO patent application WO2019071111, filed by Merck Sharp & Dohme Corp., claims novel substituted pyrazole derivatives designed to inhibit hepatitis C virus (HCV) replication.
- The application covers the chemical compounds, pharmaceutical compositions containing them, and methods for treating HCV infection.
- The international application, filed in October 2018 with priority from October 2017, serves as a basis for seeking national patent grants in numerous countries, with protection typically lasting 20 years from the priority date.
- The HCV therapeutic patent landscape is crowded, dominated by major pharmaceutical companies with extensive portfolios covering direct-acting antivirals (DAAs) targeting various viral proteins, combination therapies, and formulations.
- WO2019071111 aims to introduce next-generation compounds that must demonstrate clear novelty and inventive step over existing patented technologies.
- Successful patenting and development of these compounds could enhance Merck's antiviral pipeline and offer new treatment options, while also posing a competitive threat to incumbent therapies. Investment decisions would hinge on clinical success, IP strength, and market dynamics.
FAQs
-
What specific viral target does WO2019071111 address for HCV?
The patent application does not explicitly name a single viral target but provides in vitro data showing inhibition of HCV replication, suggesting compounds act on essential viral enzymes or proteins. Further research would be needed to confirm the precise mechanism.
-
How broad is the claim scope for the chemical compounds in WO2019071111?
The claim scope is determined by the general formula and the defined variable substituents (R groups). Broad definitions of these substituents would result in a wider scope, while narrow definitions would limit it to a more specific set of structures.
-
Can competitors develop similar HCV drugs if WO2019071111 is granted a patent?
Competitors can develop HCV drugs if they do not infringe the granted claims of WO2019071111. This involves designing around the patented chemical structures, formulations, or methods of treatment, and ensuring their products are not covered by existing prior art or other active patents.
-
What is the significance of the PCT filing for WO2019071111?
The PCT filing allows the applicant to defer the decision of which countries to seek patent protection in until later, and it provides a single application filing for a unified search and preliminary examination, simplifying the international patenting process.
-
Does WO2019071111 claim a cure for Hepatitis C?
The application claims methods of treating HCV infection. Achieving a cure is a treatment outcome, but the patent itself claims the therapeutic method and the compounds used in that method, not a guaranteed cure. Clinical trials determine the actual efficacy and cure rates.
Citations
[1] World Intellectual Property Organization. (2019). International application No. PCT/US2017/055423. WO 2019/071111 A1. Retrieved from https://patentscope.wipo.int/ (Specific document access requires searching the WIPO Patentscope database with the publication number).
